ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Yahoo! Finance
US$180 million PIPE financing to extend its cash runway beyond key upcoming clinical milestones. The company also presented promising early Phase 1 results for ORKA-001, suggesting potential for once-per-year dosing and sustained efficacy in treating psoriasis. We'll explore how the combination of positive interim ORKA-001 data and strengthened financials may reshape Oruka's investment narrative. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave What Is Oruka Therapeutics' Investment Narrative? For any potential Oruka Therapeutics shareholder, the core belief centers on the company's ability to translate its pipeline of long-acting immunology therapies into approved and commercially viable products. The recent PIPE financing and positive interim Phase 1 data for ORKA-001 now take center stage, as this capital injection extends Oruka's cash runway past some of its key Phase 2 clinical readouts. This reduces short-term financi
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ORKA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.MarketBeat
- Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]Seeking Alpha
- Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
ORKA
Earnings
- 11/12/25 - Beat
ORKA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/5/25 - Form 424B5
- ORKA's page on the SEC website